Rheumatology Medical News about ankylosing spondylitis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Can structural damage be prevented in ankylosing spondylitis
Current Opinion in Rheumatology, 06/12/09

Sieper J - A better understanding of the interaction between inflammation and new bone formation on the molecular level indicate that inflammatory molecules such as TNF-alpha inhibit osteoblasts and that a TNF-blockade induces new bone formation. Thus, TNF-blockers can only be expected to prevent new bone formation if this is coupled to inflammation and if inflammation is treated early enough. Studies on bone biomarkers in ankylosing spondylitis patients support the view that suppression of inflammation induces new bone formation.

<< Previous
New selective estrogen and androgen receptor modulators

Next >>
Factors Influencing Fracture Risk, T Score, and Management of...

Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor
Modern Rheumatology, 10/05/09 Relevance Score: 69%

Erythrocyte sedimentation rate, CRP level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
Arthritis Care and Research, 11/02/09 Relevance Score: 68%

Uncommon case of ankylosing spondylitis associated with spontaneous occurring hypoparathyroidism
Rheumatology International, 11/11/09 Relevance Score: 67%

Concomitant cervical and thoracic spinal fractures in ankylosing spondylitis: A case report and review of literature
Injury Extra, 11/05/09 Relevance Score: 67%

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 10/27/09 Relevance Score: 67%